Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown(The University of Texas MD Anderson Cancer Center), Jan C. Buckner(McGill University), William H. Yong(University of California, Irvine), Robert M. Arusell(Mayo Clinic), Kurt A. Jaeckle(Jacksonville College), David Schiff(University of Virginia Medical Center), Joon H. Uhm(Mayo Clinic), Sunil Krishnan(Mayo Clinic in Florida), Kendrith M. Rowland(Columbus Community Clinical Oncology Program), Paul S. Mischel(University of California, Los Angeles), Robert B. Jenkins(Mayo Clinic), Caterina Giannini(Mayo Clinic), Roscoe F. Morton(Mayo Clinic), Francois J. Geoffroy(Mayo Clinic), Gaspar J. Kitange(University of California, San Francisco), Bernd W. Scheithauer(Mayo Clinic), Wenting Wu(Wenzhou Institute of Industrial Science), John W. Kugler(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic)
Cited by 275
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k